CING

Cingulate Inc. (CING) | Rumor.io

Cingulate

CING

Attention (50-day avg)0%

Attention rank (50-day avg)#2,595

Bullish sentiment (50-day avg)83%

Price to earnings ratio0.02

Market capitalization70.1M

Earnings per share-3.56

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-22.4M

Social

What share of all stock conversation is about CING?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 1

The CEO of Cingulate Inc. highlights the potential of CTx-1301 in treating ADHD.
Some investors are optimistic about the stock's future, predicting a price increase to $8, $12, or even $20+ based on FDA submission and approval.
The stock has shown recent strength, with a 4% gain while short sellers are down 11%, and some investors are confident that it will continue to rise.

Generated by AI

Sentiment

Of the messages about CING that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +25	88.61% -5.78
Bearish	—	—	0% -25	11.39% +5.78

Bullish· Jun 2

The company has nearly $30 million in cash reserves, which should be sufficient to address the issues raised and execute on the resubmission process.
A raise was always expected, and the company's long-term potential remains strong, making this a long-term play.
The company's next big catalyst is the potential grant of a patent, which could drive the stock price to $20/share or higher, and potentially enter the anxiety med market with significant growth potential.

Bearish· Jun 3

$CING's recent pop of 18% may be a short-term anomaly, but it's unlikely to last given the company's poor fundamentals and the fact that most bulls are significantly underwater.
The company's core centering technology, while important, requires FDA validation and inspection, which is a lengthy process that may lead to a significant drop in the stock price once investors realize the timeline.
The stock's frothy delta hedge unwind and the large number of shorts that need to exit may lead to a significant price drop, as the only way for shorts to exit is for longs to take profit, which is unlikely given the company's poor fundamentals.

Generated by AI

Topics

Of the messages about CING that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	13.69%
Analysts	—	—	—	30.77%
Technical Analysis	—	—	—	27.34%
Controversies	—	—	—	1.22%
Earnings	—	—	—	11.13%
Macro	—	—	—	15.86%

Announcements· Feb 3

Cingulate Inc. ($CING) has announced the pricing of a $7.5 million public offering.
Cingulate Inc. ($CING) is a participant in the Battery & Precious Metals Virtual Investor Conference, where presentations are now available for online viewing.
Cingulate Inc. ($CING) is mentioned in a news article highlighting recent price movements and reaffirming a bullish trend in the gold market.

Technical Analysis· Feb 5

Cingulate Inc. ($CING) has broken out above the $6.59 resistance on high volume, with a 14.39% surge to $7.15, confirming strong momentum and a technical target of $8.61.
The breakout is supported by analyst coverage catalysts, with Stonegate updates providing a fundamental catalyst for the momentum shift.
The measured move projects an initial target of $8.66, with momentum accelerating at +14.72% and supported by fresh analyst coverage.

Generated by AI

Community

Of the messages about CING, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	75%	45.95%	51.91%
Newcomers	100%	25%	54.05%	48.09%

Regulars· Nov 7

The regulars are expecting a significant increase in the stock price, with some predicting a rise of 100% to 1000% within the next year, driven by a potential licensing deal or buyout.
The company's lead asset, CTx-1301, a phase 3-ready ADHD drug, is expected to be submitted for FDA approval soon, which could lead to a strong buyout offer and a significant increase in the stock price.
The regulars are optimistic about the company's financial health, citing a robust Q3 2024 with a $19.5M rise in working capital, and expect the stock to rise to between $10-$20 within the next 2 years.

Newcomers· Feb 5

Many new investors are focusing on Cingulate Inc. ($CING) after it broke through key resistance levels, with some seeing a potential upgrade cycle underway due to fresh analyst coverage.
The asset's price has surged by over 14% in recent days, with some traders citing strong institutional momentum and technical confirmation of a measured move toward a target of $8.66.
Analysts are updating their coverage, providing a fundamental catalyst for the asset's price increase, and some investors are expecting a continued acceleration of momentum, with a technical target aligning at $8.92.

Generated by AI

News

Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)

Tipranks Press Release.

1mo agoThe Globe and Mail

Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug

1mo agoInvesting.com

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and Controls (CMC) Work Toward NDA ResubmissionKANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended June 30, 2026,

1mo agoYahoo Finance

Cingulate publishes pharmacokinetic study on ADHD drug candidate

1mo agoInvesting.com

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

Findings further validate Cingulate’s Precision Timed Release™ (PTR™) platform and its trimodal drug delivery approachKANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision Timed Release™ (PTR™) drug delivery platform, today announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed

1mo agoYahoo Finance

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technologyKANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Phase 3 clinical trial results for its

2mo agoYahoo Finance

Also Discussed

Investors talking about CING also mention

#	Name	Attention
1	PolyPid Ltd.PYPD	0%new
2	Unicycive Therapeutics Inc.UNCY	0%new
3	FWBI - First Wave BioPharma, Inc.	——
4	SELLAS Life Sciences Group, Inc.SLS	0.56%-0.06
5	SMFL - Smart for Life, Inc.	——
6	Sera Prognostics, Inc. Class A Common StockSERA	0%0
7	LIPO - Lipella Pharmaceuticals Inc.	——
8	Grace Therapeutics, Inc.GRCE	0%new
9	CHEA - Chenghe Acquisition Co.	——
10	Os Therapies Inc.OSTX	0.1%+0.07

Cingulate Inc.

Healthcare
Biotechnology

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing drug delivery-based therapies for attention deficit/hyperactivity disorder (ADHD) and anxiety. Its Precision Timed Release platform is designed to support once-daily tablet formulations and improve how multi-dose medicines are delivered in routine treatment settings. The company’s current pipeline includes CTx-1301, a dexmethylphenidate-based candidate for ADHD in children, adolescents, and adults, and CTx-2103, a buspirone-based formulation for anxiety. Cingulate also works on additional stimulant candidates within the same platform to address common psychiatric and behavioral conditions. Based in Kansas City, Kansas, Cingulate serves the biopharmaceutical market through specialized product development centered on chronic conditions that require consistent daily dosing and targeted drug release.

Website

Location

1901 West 47th Place

Kansas City, KS, 66205

United States

Social

What share of all stock conversation is about CING?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jul 1

The CEO of Cingulate Inc. highlights the potential of CTx-1301 in treating ADHD.
Some investors are optimistic about the stock's future, predicting a price increase to $8, $12, or even $20+ based on FDA submission and approval.
The stock has shown recent strength, with a 4% gain while short sellers are down 11%, and some investors are confident that it will continue to rise.

Generated by AI

Sentiment

Of the messages about CING that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +25	88.61% -5.78
Bearish	—	—	0% -25	11.39% +5.78

Bullish· Jun 2

The company has nearly $30 million in cash reserves, which should be sufficient to address the issues raised and execute on the resubmission process.
A raise was always expected, and the company's long-term potential remains strong, making this a long-term play.
The company's next big catalyst is the potential grant of a patent, which could drive the stock price to $20/share or higher, and potentially enter the anxiety med market with significant growth potential.

Bearish· Jun 3

$CING's recent pop of 18% may be a short-term anomaly, but it's unlikely to last given the company's poor fundamentals and the fact that most bulls are significantly underwater.
The company's core centering technology, while important, requires FDA validation and inspection, which is a lengthy process that may lead to a significant drop in the stock price once investors realize the timeline.
The stock's frothy delta hedge unwind and the large number of shorts that need to exit may lead to a significant price drop, as the only way for shorts to exit is for longs to take profit, which is unlikely given the company's poor fundamentals.

Generated by AI

Topics

Of the messages about CING that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	13.69%
Analysts	—	—	—	30.77%
Technical Analysis	—	—	—	27.34%
Controversies	—	—	—	1.22%
Earnings	—	—	—	11.13%
Macro	—	—	—	15.86%

Announcements· Feb 3

Cingulate Inc. ($CING) has announced the pricing of a $7.5 million public offering.
Cingulate Inc. ($CING) is a participant in the Battery & Precious Metals Virtual Investor Conference, where presentations are now available for online viewing.
Cingulate Inc. ($CING) is mentioned in a news article highlighting recent price movements and reaffirming a bullish trend in the gold market.

Technical Analysis· Feb 5

Cingulate Inc. ($CING) has broken out above the $6.59 resistance on high volume, with a 14.39% surge to $7.15, confirming strong momentum and a technical target of $8.61.
The breakout is supported by analyst coverage catalysts, with Stonegate updates providing a fundamental catalyst for the momentum shift.
The measured move projects an initial target of $8.66, with momentum accelerating at +14.72% and supported by fresh analyst coverage.

Generated by AI

Community

Of the messages about CING, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	75%	45.95%	51.91%
Newcomers	100%	25%	54.05%	48.09%

Regulars· Nov 7

The regulars are expecting a significant increase in the stock price, with some predicting a rise of 100% to 1000% within the next year, driven by a potential licensing deal or buyout.
The company's lead asset, CTx-1301, a phase 3-ready ADHD drug, is expected to be submitted for FDA approval soon, which could lead to a strong buyout offer and a significant increase in the stock price.
The regulars are optimistic about the company's financial health, citing a robust Q3 2024 with a $19.5M rise in working capital, and expect the stock to rise to between $10-$20 within the next 2 years.

Newcomers· Feb 5

Many new investors are focusing on Cingulate Inc. ($CING) after it broke through key resistance levels, with some seeing a potential upgrade cycle underway due to fresh analyst coverage.
The asset's price has surged by over 14% in recent days, with some traders citing strong institutional momentum and technical confirmation of a measured move toward a target of $8.66.
Analysts are updating their coverage, providing a fundamental catalyst for the asset's price increase, and some investors are expecting a continued acceleration of momentum, with a technical target aligning at $8.92.

Generated by AI

Cingulate

Social

Jul 1

Bullish· Jun 2

Bearish· Jun 3

Announcements· Feb 3

Technical Analysis· Feb 5

Regulars· Nov 7

Newcomers· Feb 5

Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)

Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate publishes pharmacokinetic study on ADHD drug candidate

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Also Discussed

Cingulate Inc.

Company Information

Location

Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)

Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Cingulate publishes pharmacokinetic study on ADHD drug candidate

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

Also Discussed

Social

Jul 1

Bullish· Jun 2

Bearish· Jun 3

Announcements· Feb 3

Technical Analysis· Feb 5

Regulars· Nov 7

Newcomers· Feb 5